MEK inhibitor: Difference between revisions
Content deleted Content added
No edit summary |
|||
| Line 14: | Line 14: | ||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study http://dx.doi.org/10.1016/S1470-2045(12)70489-8 |
|||
[[Category:Cell signaling]] |
[[Category:Cell signaling]] |
||
Revision as of 13:15, 10 December 2013
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2. They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers. (See MAPK/ERK pathway#Clinical significance.)
Hence MEK inhibitors have potential for treatment of some cancers,[1] especially BRAF-mutated melanoma,[2] and KRAS/BRAF mutated colorectal cancer.[3]
Some MEK inhibitors:
- Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma.
- Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated significant improvement in PFS, and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1,NCT01933932). Other clinical trials underway include uveal melanoma, and differentiated thyroid carcinoma.
- MEK162, had phase 1 trial for biliary tract cancer and melanoma[4]
- PD-325901, for breast cancer, colon cancer, and melanoma[5]
- Cobimetinib or XL518, in a Phase III trial, in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma
- CI-1040, PD035901
References
- ^ "Clinical experience of MEK inhibitors in cancer therapy". Biochim Biophys Acta. 1773 (8): 1248–55. 2007. doi:10.1016/j.bbamcr.2006.11.009. PMID 17194493.
- ^ "ASCO: MEK Inhibitors—Alone or Paired With a BRAF Inhibitor—Increase Options, Benefits for Patients With BRAF-Mutated Advanced Melanoma". 2012.
- ^ KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. 2009
- ^ A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. 2012
- ^ MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study http://dx.doi.org/10.1016/S1470-2045(12)70489-8
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |